Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

HIGHLANDS RANCH, Colo., Oct. 19, 2021 /PRNewswire/ -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and  Candid Care Co. ("Candid") , a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network.

Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution

HIGHLANDS RANCH, Colo., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in pediatric patients after undergoing treatment using the Company's FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device.

Children in Latest Clinical Study Show Significant Reduction of Tooth Decay After Treatment with Vivos Guides

Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apnea Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research and fostering increased physician-dental collaboration in the management of obstructive-sleep apnea

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company's Technology for Obstructive Sleep Apnea

Vivos management to present at 7:00 am EDT on September 13, 2021

Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.

Implied Volatility Surging for Vivos (VVOS) Stock Options

HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced a new cooperative relationship with Empower Sleep, a San Bernardino, Calif.-based company empowering patients with affordable, accessible and personalized telemedicine sleep care, to provide critical diagnostic and medical consultation services to people across North America who suffer from OSA.

Vivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in adults; it is also used for treating sleep-disordered breathing and snoring.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance For mmRNA Oral Appliance

Vivos Therapeutics (VVOS) stock is taking off on Monday morning after revealing clearance from the FDA for its sleep apnea device. The post VVOS Stock: The Sleep Apnea Device News That Is Waking Up Vivos Therapeutics Shares appeared first on InvestorPlace.

VVOS Stock: The Sleep Apnea Device News That Is Waking Up Vivos Therapeutics Shares

Vivos Therapeutics (NASDAQ: VVOS) is surging higher today after the company announced the U.S. Food and Drug Administration granted 510(k) market clearance to its mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults. The FDA clearance paves the way for expanded insurance reimbursement coverage for the mmRNA device.

Why Vivos Therapeutics Shares Are Soaring Today

The shares of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 45% pre-market. This is why it happened.

Vivos Therapeutics Shares Increase Over 45% Pre-Market: Why It Happened

The FDA has granted 510(k) clearance to Vivos Therapeutics Inc's (NASDAQ:VVOS) mmRNA (modified mandibular Repositioning Nighttime Appliance) obstructive sleep apnea (OSA) device. The device is indicated for mild to moderate OSA, sleep-disordered breathing, and snoring in adults.

Vivos Therapeutics Stock Is Moving Higher On FDA Approval For Its Sleep Apnea Device

Part of the Vivos System Treatment, the mmRNA Device Represents a Highly Effective Non-Surgical, Non-Invasive and Non-Pharmaceutical Alternative for Patients Suffering from OSA

FDA Grants 510(k) Market Clearance to Vivos Therapeutics' mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea

HIGHLANDS RANCH, Colo., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced a more detailed summary of the national study results announced by the Company on July 13, 2021, is now available on the Company's website at: https://vivoslife.com/investor-relations/.

Detailed Summary of Study Reporting that One in Four Patients Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment Now Available on Vivos Therapeutics Website

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q2 2021 Results - Earnings Call Transcript

Second Quarter Revenue Increased Over 37% Year-Over-Year and 30% Over Q1 2021

Vivos Therapeutics Reports Second Quarter 2021 Financial Results and Operational Update

Vivos Therapeutics' mission is to rid the world of obstructive sleep apnea (OSA).

Vivos Therapeutics: Reimagining Sleep

The Vivos Institute Is Expected to Significantly Increase Vivos' Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities The Vivos Institute Is Expected to Significantly Increase Vivos' Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities

Vivos Therapeutics Opens State of the Art International Training Center In Denver

HIGHLANDS RANCH, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced results from a national study commissioned by the Company to assess patients' airway function and OSA symptoms after undergoing the Vivos treatment.

One in Four Patients in Latest Clinical Study Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment

The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 9% during intraday trading. This is why it happened.

Vivos Therapeutics Stock Price Increases Over 9%: Why It Happened

Vinco Ventures

Citius Pharmaceuticals

Diffusion Pharmaceuticals

Powerbridge Technologies Co Ltd

Seanergy Maritime Hlds

Weidai Ltd - ADR

Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?

Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021

Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q1 2021 Results - Earnings Call Transcript

Management to Host Conference Call Today at 5:00 pm ET Management to Host Conference Call Today at 5:00 pm ET

Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update

HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.00 per share.

Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

Vivos Therapeutics Announces Pricing of $24 Million Follow-On Offering

Sleeping well plays an essential role in physical health. In fact, it is part of the recovery, healing and repair process of many body functions.

News for Vivos Therapeutics Stock (VVOS)